Pendarvis plans to make his retirement effective June 30, 2023. For the remaining six months through Dec. 31, he will remain in a consulting role with ResMed.
San Diego-based ResMed plans to conduct an internal search for the successor to Pendarvis’ legal roles. The respiratory therapy developer expects to name a new global general counsel and secretary “well ahead” of his retirement date. This ensures a smooth and seamless transition, according to a news release.
Additionally, ResMed named Amy Wakeham, current VP of corporate communications and investor relations, as chief communications and investor relations officer. In taking on this role, she succeeds Pendarvis in his role leading corporate public affairs. Wakeham reports to the office of the CEO, Mick Farrell, and joins ResMed’s executive leadership team, effective April 1, 2023.
“My best wishes to Dave on a much-deserved retirement, and congratulations to Amy on her well-earned appointment,” Farrell said. “Through an internal search process, we will identify a well-qualified successor for the global general counsel role ahead of Dave’s retirement to ensure a smooth transition into these critical roles. This speaks to the overall depth of ResMed’s leadership bench strength and broad expertise across our global team of over 10,000 ResMedians as we continue to execute our strategy that will help 250 million people sleep, breathe, and live healthier lives in 2025.”
More on retiring ResMed executive David Pendarvis
Pendarvis, 64, retires after a nearly 40-year career in law and business, ResMed said. He joined the company in 2002. Before that, he spent time in private practice as a partner with the firms of Gibson Dunn and Gray Cary Ware & Freidenrich (now DLA Piper).
His roles at ResMed included global general counsel, secretary, SVP of organizational development and chief administrative officer. Pendarvis also served as interim president for Europe, Middle East, Africa, and Japan.
“Dave has been an integral part of ResMed for over 20 years, helping guide the company into and through its transformation from the pioneer of sleep apnea treatment to a $30 billion-plus global leader in digital health and cloud-connected medical devices,” said Farrell. “On behalf of the entire management team and the board, I want to thank Dave for his two decades of dedicated service and exemplary leadership that has helped build the industry-leading company that ResMed is today.”